These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16252586)

  • 21. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
    Bin-Abbas BS; Al-Ashwal AA; Al-Zayed ZS; Sakati NA
    Saudi Med J; 2004 Nov; 25(11):1772-3. PubMed ID: 15573233
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    Rauch F; Plotkin H; Zeitlin L; Glorieux FH
    J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
    Onwuneme C; Abdalla K; Cassidy N; Hensey O; Ryan S
    Arch Dis Child; 2007 Dec; 92(12):1087. PubMed ID: 18032639
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Bembi B; Parma A; Bottega M; Ceschel S; Zanatta M; Martini C; Ciana G
    J Pediatr; 1997 Oct; 131(4):622-5. PubMed ID: 9386671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
    Dimeglio LA; Ford L; McClintock C; Peacock M
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 33. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
    Lin CH; Chien YH; Peng SF; Tsai WY; Tung YC; Lee CT; Chien CC; Hwu WL; Lee NC
    Pediatr Neonatol; 2014 Aug; 55(4):306-11. PubMed ID: 24486247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biphosphonates and osteogenesis imperfecta in children].
    Gandon-Laloum S
    Arch Pediatr; 2009 Jul; 16(7):1085-9. PubMed ID: 19423303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings.
    Li G; Jin Y; Levine MAH; Hoyer-Kuhn H; Ward L; Adachi JD
    Acta Paediatr; 2018 Mar; 107(3):534-537. PubMed ID: 29154388
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P; Silverwood B; Tillmann V; Bishop NJ
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.